Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Regeneron Pharmaceuticals has announced a new clinical study titled ‘A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-ATLAS)’. The study aims to assess the safety and efficacy of two experimental drugs, REGN7508 and REGN9933, in preventing blood clots in patients with atrial fibrillation, comparing their effects to the existing drug, Apixaban.
The interventions being tested are REGN7508 and REGN9933, both monoclonal antibodies designed to prevent blood clot formation in patients with atrial fibrillation. These drugs are being compared to Apixaban, a currently available treatment for the same condition.
This Phase 2 study is interventional and randomized, employing a parallel assignment model. It is single-masked, with the outcomes assessor being the only party blinded to the treatment allocation. The primary purpose of the study is prevention.
The study is set to begin on September 9, 2025, with the last update submitted on the same date. These dates are crucial as they mark the commencement of participant recruitment and the latest information available on the study’s progress.
The initiation of this study could influence Regeneron’s stock performance positively, as successful results may enhance their product portfolio in the competitive anticoagulation market. Investors should monitor this development closely, considering the potential impact on market dynamics and competitor responses.
The study is currently not yet recruiting, with further details available on the ClinicalTrials portal.